Advisor and Interim Executive for Scaling MedTech Companies
Advisor and Interim Executive
for Scaling MedTech Companies
When the organisation no longer scales with the product
When the organisation no longer scales with the product
When the organisation no longer scales with the product
Growth rarely slows because regulation becomes more complex. It slows when governance, decision-making and the Management System no longer support the next phase of growth.
I work with MedTech leadership teams when those structures need to evolve, as an advisor or in an interim executive role.
Growth rarely slows because regulation becomes more complex. It slows when governance, decision-making and the Management System no longer support the next phase of growth.
I work with MedTech leadership teams when those structures need to evolve, as an advisor or in an interim executive role.
Growth rarely slows because regulation becomes more complex. It slows when governance, decision-making and the Management System no longer support the next phase of growth.
I work with MedTech leadership teams when those structures need to evolve, as an advisor or in an interim executive role.
Discuss your situation
SITUATIONS
When I am brought in
When I am brought in
When I am brought in
Usually not because more operational capacity is needed. Usually because something structural has started to show up in execution.
Usually not because more operational capacity is needed. Usually because something structural has started to show up in execution.
Usually not because more operational capacity is needed. Usually because something structural has started to show up in execution.
Execution has started to slow.
Execution has started to slow.
Execution has started to slow.
Decisions take longer. Teams build workarounds. Functions protect their own scope. The work still gets done, but it costs more than it used to.
Decisions take longer. Teams build workarounds. Functions protect their own scope. The work still gets done, but it costs more than it used to.
Decisions take longer. Teams build workarounds. Functions protect their own scope. The work still gets done, but it costs more than it used to.
International expansion.
International expansion.
International expansion.
EU, FDA and international growth add coordination layers faster than most organisations add structure. The difficulty is rarely the regulation itself. It is that several markets are handled through decision paths that were built for one.
EU, FDA and international growth add coordination layers faster than most organisations add structure. The difficulty is rarely the regulation itself. It is that several markets are handled through decision paths that were built for one.
EU, FDA and international growth add coordination layers faster than most organisations add structure. The difficulty is rarely the regulation itself. It is that several markets are handled through decision paths that were built for one.
The operating model has been outgrown.
The operating model has been outgrown.
The operating model has been outgrown.
Structures that worked at an earlier stage become increasingly difficult to operate as the organisation grows. At that point more effort does not help, because effort is not the constraint.
Structures that worked at an earlier stage become increasingly difficult to operate as the organisation grows. At that point more effort does not help, because effort is not the constraint.
Structures that worked at an earlier stage become increasingly difficult to operate as the organisation grows. At that point more effort does not help, because effort is not the constraint.
Investor and diligence pressure.
Investor and diligence pressure.
Investor and diligence pressure.
Growth-stage companies are assessed not only on what they have documented, but on whether the organisation can execute reliably. Structural weaknesses often become visible in diligence, usually at an inconvenient moment.
Growth-stage companies are assessed not only on what they have documented, but on whether the organisation can execute reliably. Structural weaknesses often become visible in diligence, usually at an inconvenient moment.
Growth-stage companies are assessed not only on what they have documented, but on whether the organisation can execute reliably. Structural weaknesses often become visible in diligence, usually at an inconvenient moment.
PERSPECTIVE
Where regulatory friction usually comes from
Where regulatory friction usually comes from
Where regulatory friction usually comes from
Regulatory friction is often treated where it becomes visible: in Quality, Regulatory, documentation or process control.
Sometimes that is exactly where the problem sits.
But sometimes the regulatory issue is only the late signal of a structural decision made much earlier.
Ownership was unclear. A process was designed for a smaller organisation. An interface evolved without anyone
consciously designing it.
By the time the problem becomes visible as regulatory friction, it may have been developing elsewhere in the organisation
for quite some time.
The response is often more capacity, more documentation or more control.
But before adding any of them, I want to understand what the friction is telling us about the system underneath.
Regulatory friction is often treated where it becomes visible: in Quality, Regulatory, documentation or process control.
Sometimes that is exactly where the problem sits.
But sometimes the regulatory issue is only the late signal of a structural decision made much earlier. Ownership was unclear. A process was designed for a smaller organisation. An interface evolved without anyone consciously designing it.
By the time the problem becomes visible as regulatory friction, it may have been developing elsewhere in the organisation for quite some time.
The response is often more capacity, more documentation or more control.
But before adding any of them, I want to understand what the friction is telling us about the system underneath.
Regulatory friction is often treated where it becomes visible: in Quality, Regulatory, documentation or process control.
Sometimes that is exactly where the problem sits.
But sometimes the regulatory issue is only the late signal of a structural decision made much earlier. Ownership was unclear. A process was designed for a smaller organisation. An interface evolved without anyone consciously designing it.
By the time the problem becomes visible as regulatory friction, it may have been developing elsewhere in the organisation
for quite some time.
The response is often more capacity, more documentation or more control.
But before adding any of them, I want to understand what the friction is telling us about the system underneath.
EXPERIENCE
Built from executive experience
Built from executive experience
Built from executive experience
My perspective comes from more than two decades working inside MedTech organisations, across Quality and Regulatory, executive leadership and transformation.
Different ownership.
Different stages.
Different regulatory challenges.
The recurring question has been the same: what has to change in the organisation when the structures that brought it this far are no longer enough for what comes next?
My perspective comes from more than two decades working inside MedTech organisations, across Quality and Regulatory, executive leadership and transformation.
Different ownership.
Different stages.
Different regulatory challenges.
The recurring question has been the same: what has to change in the organisation when the structures that brought it this far are no longer enough for what comes next?
My perspective comes from more than two decades working inside MedTech organisations, across Quality and Regulatory, executive leadership and transformation.
Different ownership.
Different stages.
Different regulatory challenges.
The recurring question has been the same: what has to change in the organisation when the structures that brought it this far are no longer enough for what comes next?
Venture-backed startups.
Private equity-backed businesses.
Family-owned companies.
Multinational organisations.
Venture-backed startups.
Private equity-backed businesses.
Family-owned companies.
Multinational organisations.
Venture-backed startups.
Private equity-backed businesses.
Family-owned companies.
Multinational organisations.
More about my perspective
WORKING TOGETHER
How this works in practice
How this works in practice
How this works in practice
Some of this work is advisory, some of it means taking executive responsibility inside the organisation for a period. Sparring with a leadership team, a focused review of one structure, a longer transformation, or an interim role while something is rebuilt.
The right format usually becomes obvious once the actual problem is on the table.
Some of this work is advisory, some of it means taking executive responsibility inside the organisation for a period. Sparring with a leadership team, a focused review of one structure, a longer transformation, or an interim role while something is rebuilt.
The right format usually becomes obvious once the actual problem is on the table.
My perspective comes from more than two decades working inside MedTech organisations, across Quality and Regulatory, executive leadership and transformation.
Different ownership.
Different stages.
Different regulatory challenges.
The recurring question has been the same: what has to change in the organisation when the structures that brought it this far are no longer enough for what comes next?
How I work
EXECUTIVE SESSIONS
The questions leadership cannot delegate
The questions leadership cannot delegate
The questions leadership cannot delegate
Some responsibilities stay with the CEO, however much of the work moves into functions, processes and specialised roles as the company grows.
These sessions create a space to examine those responsibilities differently. Regulatory requirements provide the structure, but the conversation is about leadership, governance and what an executive needs to be able to see, question and decide.
One series for founders building the organisation around the product, one for executives leading one that has already grown.
Some responsibilities stay with the CEO, however much of the work moves into functions, processes and specialised roles as the company grows.
These sessions create a space to examine those responsibilities differently. Regulatory requirements provide the structure, but the conversation is about leadership, governance and what an executive needs to be able to see, question and decide.
One series for founders building the organisation around the product, one for executives leading one that has already grown.
Some responsibilities stay with the CEO, however much of the work moves into functions, processes and specialised roles as the company grows.
These sessions create a space to examine those responsibilities differently. Regulatory requirements provide the structure, but the conversation is about leadership, governance and what an executive needs to be able to see, question and decide.
One series for founders building the organisation around the product, one for executives leading one that has already grown.
Explore Executive Sessions
Scaling pressure rarely announces itself clearly
Scaling pressure rarely announces itself clearly
Scaling pressure rarely announces itself clearly
Sometimes it shows up as slower execution. Sometimes as governance friction, investor questions, or a growing sense that everything takes more effort than it should.
If that sounds familiar, the conversation is probably worth having.
Sometimes it shows up as slower execution. Sometimes as governance friction, investor questions, or a growing sense that everything takes more effort than it should.
If that sounds familiar, the conversation is probably worth having.
Sometimes it shows up as slower execution. Sometimes as governance friction, investor questions, or a growing sense that everything takes more effort than it should.
If that sounds familiar, the conversation is probably worth having.
Discuss your situation
© 2026 Olaf H. Nitz Advisory. All rights reserved.
© 2026 Olaf H. Nitz Advisory. All rights reserved.
© 2026 Olaf H. Nitz Advisory. All rights reserved.